Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Solitary plasmacytoma (SP) is characterized by a localized mass of clonal plasma cells with no or minimal bone marrow plasmacytosis. It can present either as EMP or SBP. Radiotherapy is the

  • 0 views
  • 13 May, 2022
  • 1 location
  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

bone marrow procedure
plasmacytoma
immunohistochemistry
aspirin
revlimid
  • 0 views
  • 18 Feb, 2022
  • 7 locations
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of …

carfilzomib
monoclonal antibodies
growth factor
plasmacytoma
induction therapy
  • 27 views
  • 02 May, 2022
  • 4 locations
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT). This study is designed to see whether an investigational cellular product of immune cells obtained from a …

cell transplantation
  • 0 views
  • 12 May, 2022
  • 1 location
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)

This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely …

vasectomy
serum immunoglobulin a
cyclophosphamide
plasmacytoma
bortezomib
  • 3 views
  • 18 Feb, 2022
  • 1 location
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

refractory multiple myeloma
monoclonal antibodies
warfarin
plasmacytoma
aspirin
  • 36 views
  • 29 Apr, 2022
  • 7 locations